

ASX ANNOUNCEMENT (ASX: RSH)

12th April 2023

RESPIRI ANNOUNCES APPOINTMENT OF EXPERIENCED HEALTHCARE/REMOTE PATIENT MONITORING (RPM) EXECUTIVE AS HEAD OF USA BUSINESS

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory remote patient monitoring is pleased to announce that following an extensive executive search, Mr. William Sigsbee has been appointed as the Chief Commercial Officer for the US market reporting directly to Respiri CEO and Managing Director, Marjan Mikel. With more than 30 years of healthcare experience in medical devices, services and software solutions, including previous roles as Chief Executive Officer (CEO), Mr. Sigsbee brings a wealth of knowledge around the US healthcare market, partnership strategy and distribution of leading-edge patient engagement technologies.

The Respiri plan was always to build a local US business team to manage the growing US RPM business with existing and new clients. With the Company's business model now validated and working, generating income for Respiri and other related stakeholders and customers across the USA, the time is right to create a team that will support US operations and continue to accelerate RPM wheezo® programs enrolment with existing blue chip healthcare customers and to continue build the new customer portfolio.

All efforts are now invested in scaling US operations and growing RPM patient numbers and revenues. Mr Sigsbee will be supported by Respiri CEO, Marjan Mikel who will continue to provide overall Company leadership and on-the-ground support in the USA. The Australian team will maintain the successful support of these US business endeavours with the US Respiri team to be built prudently, over time, to adequately support the growing RPM business in the USA and the operations required to continue this successful journey.

Mr Sigsbee led a healthcare SaaS company, Medicom Health Interactive, as CEO, serving more than 120 of the largest healthcare systems in the US. He was instrumental in developing and executing product, pricing, marketing sales and channel strategies for health assessment tools that are in use today in more than 1000 hospitals. He led the company from pre-revenue custom software developer, to a healthcare platform SaaS company, growing at 30% CAGR, with 89% GM & 15% EBITDA in 2020. The company was successfully sold in December of 2021 to Genstar Capital HIG Equity. Most recently, following the sale, Mr Sigsbee worked as a consultant with a number of companies in the Remote Patient Monitoring/Telehealth space, building go-to-market and patient-engagement strategy.

CEO and Managing Director of Respiri, Mr Marjan Mikel said "We continue to make significant business progress in the US and our opportunity is continue this traction and growth through ensuring continuity of business support with a local Respiri Leader. Will's pedigree in our US business space is what we need to continue to deliver world class RPM solutions to our clients. His experience and relationships in the US healthcare space are first class and will serve Respiri very well. This is an exciting next chapter in our growing US business"

Will Sigsbee, Chief Commercial Officer, USA commented, "I am excited to be working with Respi during a time when telehealth and RPM solutions are becoming an integral part of all healthcare organizations' patient engagement strategy. Respi's technology brings an innovative new approach to the treatment and management of Chronic respiratory conditions and will allow thousands of physicians to treat and manage patients remotely."

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respi Limited
P: +61 408 462 873
E: marjan@respi.co

Mr Nicholas Smedley
Executive Chairman
Respi Limited
P: +61 447 074 160
E: nicholas@respi.co

This ASX announcement dated 10th April 2023 has been authorised for release by the Board of Directors of Respi Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respi Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking

statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiro only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.